In situ expression of CD40 and CD40 ligand in psoriasis

被引:31
|
作者
Ohta, Y
Hamada, Y
机构
[1] Yokohama Natl Univ, Fac Div Dermatol, Yokohama, Kanagawa 240, Japan
[2] Kitasato Univ, Sch Med, Dept Dermatol, Sagamihara, Kanagawa 228, Japan
关键词
psoriasis; CD40; ligand; immunohistochemistry;
D O I
10.1159/000078582
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: The interaction between CD40 and CD40 ligand (CD40L) provides a signal that contributes to the initiation of cellular immune responses. However, little information on the in vivo expression of CD40 and CD40L in cutaneous inflammation has been reported. Objective: To investigate the potential role of CD40-mediated signals in the pathogenesis of psoriasis. Materials and Methods: In situ CD40 and CD40L expression was examined immunohistochemically in different stages of psoriatic lesions: fully developed and initial pinpoint. Results: In normal skin, faintly positive immunoreactivity for CD40 was seen in the basal keratinocytes and dermal endothelial cells. These showed almost the same intensity as that seen in psoriatic lesional skin. In the dermal infiltrates of psoriatic lesions, CD40 was intensely expressed and some of these positive cells appeared to be dendritic in shape. Whereas CD40 expression was observed almost in all specimens of psoriatic lesions, the expression of CD40L was predominantly detected in the initial pinpoint lesions of psoriasis. These seemed to be distributed close to CD40-positive cells. Conclusion: These results suggested that CD40L-triggered signals could be involved in the early stage of psoriatic lesion formation. Copyright (C) 2004 S. Karger AG, Basel.
引用
收藏
页码:21 / 28
页数:8
相关论文
共 50 条
  • [21] Association between serum levels of soluble CD40/CD40 ligand and organ damage in hypertensive patients
    Yuan, Ming
    Ohishi, Mitsuru
    Wang, Lin
    Raguki, Hiromi
    Wang, Haichang
    Tao, Ling
    Ren, Jun
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2010, 37 (08) : 848 - 851
  • [22] Soluble CD40 ligand, platelet surface CD40 ligand, and total platelet CD40 ligand in atrial fibrillation - Relationship to soluble P-selectin, stroke risk factors, and risk factor intervention
    Choudhury, Anirban
    Chung, Irene
    Panja, Nimai
    Patel, Jeetesh
    Lip, Gregory Y. H.
    CHEST, 2008, 134 (03) : 574 - 581
  • [23] Glucocorticoids inhibit CD40 ligand expression of peripheral CD4+ lymphocytes
    Bischof, F
    Melms, A
    CELLULAR IMMUNOLOGY, 1998, 187 (01) : 38 - 44
  • [24] Cloning, sequence analysis and expression of ovine CD154 (CD40 ligand)
    Oledzka, Gabriela
    Li, Bo
    Kay, Graham William
    Chomicz, Lidia
    Stankiewicz, Miroslaw
    MOLECULAR IMMUNOLOGY, 2007, 44 (05) : 741 - 746
  • [25] Increase of intracellular calcium is the essential signal for the expression of CD40 ligand
    Nusslein, HG
    Frosch, KH
    Woith, W
    Lane, P
    Kalden, JR
    Manger, B
    EUROPEAN JOURNAL OF IMMUNOLOGY, 1996, 26 (04) : 846 - 850
  • [26] Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes
    Koshy, M
    Berger, D
    Crow, MK
    JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (03): : 826 - 837
  • [27] CD40 ligand as a potential biomarker for atherosclerotic instability
    Wang, Jing-Hua
    Zhang, Yong-Wei
    Zhang, Ping
    Deng, Ben-Qiang
    Ding, Suju
    Wang, Zhong-Kui
    Wu, Tao
    Wang, Jian
    NEUROLOGICAL RESEARCH, 2013, 35 (07) : 693 - 700
  • [28] The role of CD40 ligand in systemic lupus erythematosus
    Yazdany, J
    Davis, J
    LUPUS, 2004, 13 (05) : 377 - 380
  • [29] CD40 LIGAND IS FUNCTIONALLY EXPRESSED ON HUMAN EOSINOPHILS
    GAUCHAT, JF
    HENCHOZ, S
    FATTAH, D
    MAZZEI, G
    AUBRY, JP
    JOMOTTE, T
    DASH, L
    PAGE, K
    SOLARI, R
    ALDEBERT, D
    CAPRON, M
    DAHINDEN, C
    BONNEFOY, JY
    EUROPEAN JOURNAL OF IMMUNOLOGY, 1995, 25 (03) : 863 - 865
  • [30] Transcriptional activity of the distal CD40 ligand promoter
    Lobo, FM
    Xu, SH
    Lee, C
    Fuleihan, RL
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2000, 279 (01) : 245 - 250